评价脂溶性维生素纳米胶束制剂在囊性纤维化患者中的效率:一项随机对照试验的研究方案
本研究为在伊朗马什哈德阿克巴尔儿童医院开展的前瞻性单盲对照试验,纳入囊性纤维化患儿,对照组接受常规脂溶性维生素标准制剂,干预组接受脂溶性维生素纳米胶束制剂治疗3个月,主要结局为血清脂溶性维生素水平,次要结局包括Shwachman-Kulczycki评分、人体测量学指标和生活质量,旨在评估纳米胶束制剂能否使患儿达到适宜的血清维生素水平。
要点
- 囊性纤维化患者即使接受有效胰酶制剂和CF专用维生素,仍常见脂溶性维生素(A、D、E、K)缺乏。
- 该前瞻性单盲对照试验在伊朗马什哈德阿克巴尔儿童医院开展,干预组接受纳米胶束脂溶性维生素制剂3个月。
- 主要结局为血清脂溶性维生素水平,次要结局包括Shwachman-Kulczycki评分、人体测量学指标和生活质量。
核心结论
- 由于囊性纤维化患者持续存在脂溶性维生素缺乏,纳米胶束制剂可作为囊性纤维化治疗中脂溶性维生素的一种新递送方法提出。
研究设计与样本
- 前瞻性、单盲对照试验,在伊朗马什哈德阿克巴尔儿童医院开展,纳入符合入选标准的囊性纤维化患者。
- 对照组接受与常规囊性纤维化治疗相似的脂溶性维生素标准制剂,干预组接受脂溶性维生素纳米胶束制剂治疗3个月。
- 主要结局为血清脂溶性维生素水平测定;次要结局为Shwachman-Kulczycki评分临床评估、人体测量学指标和生活质量。
- 结局在3个月前和3个月后评估。
- 试验注册:伊朗临床试验注册中心IRCT20220415054541N1,注册日期2022年7月23日。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cystic fibrosis is an inherited disease, which is caused by the CFTR protein defects due to mutations in the CFTR gene. Along with CFTR dysfunction, exocrine pancreatic insufficiency plays a key role in persistent fat malabsorption in CF patients; therefore, deficiency of fat-soluble vitamins (A, D, E, and K) is still a therapeutic challenge. Even with efficient pancreatic enzyme medication and CF-specific vitamins, many patients with CF have fat-soluble vitamins deficiency. The present study aims to evaluate the efficiency of nanomicelle formulation of fat-soluble vitamins in children with CF in order to achieve the appropriate serum levels of these vitamins. METHODS: This prospective, single-blind control trial will be conducted at the Akbar Children's Hospital in Mashhad, Iran. Patients with CF will be enrolled based on the eligibility criteria. The control group will receive the standard formulation of fat-soluble vitamins similar to the routine CF treatment, and for the intervention group, the nanomicelle formulation of fat-soluble vitamins will be administered for 3 months. The primary outcome of this study is the measurement of serum levels of fat-soluble vitamins. The secondary outcomes are clinical assessment by the Shwachman-Kulczycki score, anthropometrics, and quality of life. Outcomes will be assessed before and after 3 months. DISCUSSION: Due to persistent fat-soluble vitamin deficiency in CF disease, the nanomicelle formulation could be proposed as a new delivery method of fat-soluble vitamins in the treatment of cystic fibrosis. TRIAL REGISTRATION: Iranian Registry of Clinical Trials IRCT20220415054541N1. Registered on July 23, 2022.
引用
- Soleimanzadeh M, Talebi S, Jaafari MR, et al. Evaluation of the efficiency of nanomicellar formulation of fat-soluble vitamins in patients with cystic fibrosis: the study protocol for a randomized controlled trial. Trials. 2024. PMID: 38229125. doi:10.1186/s13063-023-07896-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。